Search
Cancer research technologies for biomarker discovery, liquid biopsy research and more
From identifying and characterizing potential biomarkers to sensitively detecting and quantifying circulating nucleic acids in blood and other biofluids, Applied BiosystemsTM solutions for real-time PCR, digital PCR and other genetic analysis technologies help researchers investigate the molecular changes associated with cancer.
Explore trusted cancer research technologies, educational resources and workflow solutions designed to support deeper insights into cancer biology and accelerate your research discoveries.
Resources
eBooks
On-demand webinars
Selecting biomarker methods for evolving oncology research workflows
Explores how to make informed methodological decisions when implementing and combining approaches for biomarker detection.
As biomarker testing becomes central to precision oncology workflows, research laboratories are under increasing pressure to select and integrate methods that deliver reliable results across diverse sample types, including liquid biopsy.
This webinar explores how to make informed methodological decisions when implementing and combining approaches for biomarker detection.
Through real‑world examples, attendees will gain insight into balancing sensitivity, turnaround time, and sample constraints, alongside key considerations for verification and workflow design. Watch in order to better align your research laboratory strategy with evolving clinical and translational research demands.
Watch this webinar to:
- Gain an overview of NGS, qPCR and dPCR targeted for biomarker detection across FFPE, cytology, and liquid biopsy samples
- Learn to integrate multiple methodologies for optimal results, including key considerations like limitations, workflows, and turnaround time
- Discover best practices for analytical verification to help ensure reliable implementation in research laboratories
About the speaker
Javier Hernández Losa has a PhD in biology from the Universidad Autonoma de Madrid (2005). He has led the molecular biology laboratory within the pathology service of the Hospital Universitari Vall d´Hebron in Barcelona since 2006. The laboratory specializes in the study of biomarkers, mainly in tissue samples, and these studies have recently been extended to liquid biopsy samples. Over the last few years, he has coordinated three PhD theses and supervises several master’s projects based on the study of cell‑free DNA (cfDNA) and exosomes, both in in vitro models and in clinical samples from patients with advanced tumors.
Advancing cancer research through liquid biopsy and circulating biomarkers
Examine the current landscape of liquid biopsy research and its growing potential for cancer detection, monitoring, and treatment decision making.
This webinar examines the current landscape of liquid biopsy research and its growing potential for cancer detection, monitoring, and treatment decision making. Attendees will gain practical insight into how these approaches are helping address key challenges in oncology research and paving the way for more research into responsive and personalized cancer care.
Attend this webinar to:
- Understand how circulating tumor DNA (ctDNA), DNA methylation profiles, and non-coding RNAs overcome limitations of tissue biopsies by capturing tumor heterogeneity and molecular dynamics in real time
- Learn how liquid biopsy biomarkers can be used for early detection, prognosis, treatment selection, and disease monitoring, with practical examples from bladder cancer (urine-based ctDNA and methylation) and head and neck cancer (circulating microRNAs)
- Gain insight into emerging technologies and verification efforts that are accelerating the adoption of liquid biopsy into routine care, enabling more personalized, adaptive cancer management
About the speaker
Dr. Matteo Allegretti is a Senior Researcher in the Translational Oncology Research Unit at the Regina Elena National Cancer Institute in Rome, Italy. His work, together with his research team, is primarily focused on liquid biopsy analysis for both clinical and research applications. Their activities include the management of multiple types of biological samples, with a strong emphasis on biomarker research, as well as the identification and validation of biomarkers for translational purposes.
dPCR in liquid biopsy for management and detection of cancer
Learn about the analysis of ctDNA by dPCR, which has applications in non-invasive biomarker testing, tumor bulk analysis and more.
Liquid biopsies utilize cell free DNA (cfDNA) derived from both normal and cancerous cells. The component of cfDNA that is released from cancer cells is commonly referred to as circulating tumor DNA, or ctDNA.
Attend this webinar to learn about the analysis of ctDNA by dPCR, which has several applications:
- ctDNA genotyping can be used for non invasive biomarker testing, which is especially relevant in testing lung cancer samples
- ctDNA levels correlate well with tumor bulk
- ctDNA levels are of prognostic significance, as ctDNA levels have been shown to correlate well with survival outcomes
About the speaker
Dr. Atocha Romero is a principal investigator and director of the liquid biopsy laboratory at Puerta de Hierro University Hospital in Madrid, Spain, where she has led a translational precision oncology research program since 2015. Her research focuses on the clinical implementation of liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) and minimal residual disease (MRD), to improve treatment selection and disease monitoring in lung cancer. She has authored more than 100 peer-reviewed publications and has played a leading role in landmark clinical-translational studies, including the NADIM, NADIM II, REAL-NADIM, and APOLO programs. Dr. Romero is internationally recognized for her leadership in translational cancer research.
Other resources
Products
Explore our solutions for cancer research, with a complete workflow of technologies for biomarker discovery, molecular profiling, liquid biopsy research, targeted analysis and everything in between.
Customer stories
Blog
FAQs
Cancer researchers use a range of molecular analysis technologies to investigate genetic and molecular changes associated with cancer. Applied Biosystems real-time PCR, digital PCR and genetic analysis solutions can support applications such as biomarker discovery, mutation analysis, gene expression research and molecular profiling.
Liquid biopsy research examines cancer-associated biomarkers found in blood and other biofluids, including circulating tumor DNA (ctDNA) and other circulating nucleic acids. Sensitive molecular analysis technologies such as digital PCR can help researchers detect and quantify low-abundance targets for studies of cancer biology and biomarker development.
Cancer biomarker research involves identifying and characterizing molecular features that may provide insights into cancer biology. Researchers can use PCR and genetic analysis technologies to study DNA and RNA targets, evaluate genetic variation and gene expression and further investigate potential biomarkers.
Digital PCR enables highly sensitive, precise nucleic acid quantification and can be used to investigate rare genetic variants and low-abundance targets. These capabilities make digital PCR particularly useful for cancer research involving circulating biomarkers, liquid biopsy samples and other applications where target concentrations may be low.
Applied Biosystems solutions offers molecular analysis technologies and workflows that can support cancer research from biomarker discovery through targeted analysis. Solutions include real-time PCR, digital PCR, genetic analysis instruments, assays, reagents, software and educational resources for applications such as liquid biopsy research and molecular profiling.
For Research Use Only. Not for use in diagnostic procedures.